|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1995-7-19
|
|
pubmed:abstractText |
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-1569452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-1870152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2213101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2446744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2679456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2685181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2804986,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-2809685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-3262413,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-3497883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-3804370,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-6332379,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-8410122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-8453558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7779731-8468720
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1319-21
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7779731-Adolescent,
pubmed-meshheading:7779731-Adult,
pubmed-meshheading:7779731-Aged,
pubmed-meshheading:7779731-Female,
pubmed-meshheading:7779731-Humans,
pubmed-meshheading:7779731-Immunotherapy,
pubmed-meshheading:7779731-Interferon-alpha,
pubmed-meshheading:7779731-Interleukin-2,
pubmed-meshheading:7779731-Male,
pubmed-meshheading:7779731-Melanoma,
pubmed-meshheading:7779731-Middle Aged,
pubmed-meshheading:7779731-Neoplasm Metastasis,
pubmed-meshheading:7779731-Recombinant Proteins,
pubmed-meshheading:7779731-Survival Rate,
pubmed-meshheading:7779731-Time Factors
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
|
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
